The stock has a 36-month beta value of 1.75. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ENOV is 55.15M, and at present, short sellers hold a 7.69% of that float. On September 27, 2024, the average trading volume of ENOV was 634.78K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ENOV) stock’s latest price update
Enovis Corp (NYSE: ENOV)’s stock price has gone rise by 2.26 in comparison to its previous close of 42.41, however, the company has experienced a -3.67% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-09-09 that WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) — Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company’s U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis’ Reconstructive (Recon) Business Group.
ENOV’s Market Performance
ENOV’s stock has fallen by -3.67% in the past week, with a monthly drop of -4.68% and a quarterly drop of -3.43%. The volatility ratio for the week is 2.63% while the volatility levels for the last 30 days are 2.89% for Enovis Corp. The simple moving average for the past 20 days is -0.99% for ENOV’s stock, with a -17.02% simple moving average for the past 200 days.
Analysts’ Opinion of ENOV
Many brokerage firms have already submitted their reports for ENOV stocks, with JP Morgan repeating the rating for ENOV by listing it as a “Neutral.” The predicted price for ENOV in the upcoming period, according to JP Morgan is $53 based on the research report published on June 13, 2024 of the current year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ENOV reach a price target of $72. The rating they have provided for ENOV stocks is “Overweight” according to the report published on February 13th, 2024.
UBS gave a rating of “Buy” to ENOV, setting the target price at $75 in the report published on January 22nd of the current year.
ENOV Trading at -2.69% from the 50-Day Moving Average
After a stumble in the market that brought ENOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.31% of loss for the given period.
Volatility was left at 2.89%, however, over the last 30 days, the volatility rate increased by 2.63%, as shares sank -4.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.48% lower at present.
During the last 5 trading sessions, ENOV fell by -3.67%, which changed the moving average for the period of 200-days by -12.44% in comparison to the 20-day moving average, which settled at $43.71. In addition, Enovis Corp saw -22.58% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENOV
Current profitability levels for the company are sitting at:
- -0.04 for the present operating margin
- 0.55 for the gross margin
The net margin for Enovis Corp stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -3.18, with -2.17 for asset returns.
Based on Enovis Corp (ENOV), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 0.42. The interest coverage ratio of the stock is -1.66.
Currently, EBITDA for the company is 194.39 million with net debt to EBITDA at 10.1. When we switch over and look at the enterprise to sales, we see a ratio of 1.99. The receivables turnover for the company is 4.85for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.26.
Conclusion
To sum up, Enovis Corp (ENOV) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
